Quantification of Farnesylated Progerin in Hutchinson-Gilford Progeria Patient Cells by Mass Spectrometry.
Level 5 - mechanism / opinion, no new human data
Analytical method development in patient cell models (bench research)
PubMed 36233036 · doi:10.3390/ijms231911733
What was done
The authors developed a non-immunological, targeted mass spectrometry (MS) assay using isotope-labeled internal standards to quantify endogenous levels of mature wild-type lamin A and farnesylated progerin in cells from patients with Hutchinson-Gilford progeria syndrome (HGPS).
What was found
The abstract describes the targeted MS approach as capable of quantifying wild-type lamin A and farnesylated progerin in HGPS patient cells, offering an alternative to immunological detection methods. No numerical validation metrics, concentrations, sample sizes, or assay performance figures are reported in the abstract.
Why it matters
The ratio of progerin to mature lamin A correlates with HGPS severity. A specific, non-antibody-based quantification assay provides an objective tool to assess target engagement and drug efficacy in clinical trials evaluating progerin-lowering or farnesylation-inhibiting therapies.
Limits
The abstract reports no quantitative performance metrics (such as limit of detection, precision, linear range, or recovery), omits the number or characteristics of patient cell samples analyzed, and demonstrates assay implementation only in cell models rather than patient tissue or longitudinal clinical trial cohorts.
Cited by
- supports Hutchinson-Gilford progeria syndrome is characterized by the accumulation of progerin, a mutant lamin protein carrying a persistent farnesyl tag.